Pharsight

Methylin generic

Methylin is a medication owned by Specgx Llc. It first hit the market on December 19, 2002. Its active ingredient is methylphenidate hydrochloride and it is available in solution;oral dosage forms.

When will Methylin generic be available?

The drugs patents protect Methylin from generic competition. With a total of 1 patent, Methylin generic is possible to be available after the expiration of the last patent on October 7, 2024. The availability of Methylin generic version after this date may be due to a Paragraph IV challenge, which allows generic manufacturer to challenge a patent's validity.

Methylin uses

Methylin, containing methylphenidate hydrochloride, is typically used to treat disorders like attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It aids in increasing attention and decreasing impulsiveness and hyperactivity by changing the amounts of certain natural substances in the brain.

Methylin patent expiration

There is 1 registered patent for Methylin, out of which none are expired. The last patent, US7691880, titled 'Methylphenidate solution and associated methods of administration and production', expires on October 7, 2024. Keep reading for more details on Methylin generic release date and patents. Below are the details of the patent:

Methylin dosage

Want to ask something?